![Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma](https://mms.businesswire.com/media/20220104005887/en/611316/22/Exelixis_Logo_JPG.jpg)
Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy an
Advertising Press Release Distribution | Reality TV | Lifestyle Magazine | Kiev Plastic Surgery
Advertising Business Newspaper | Miami News | Lifestyle Magazine | Fashion Magazine | Digital Newspaper | Lifestyle Magazine | Woman Magazine | Lifestyle News | Politic News | Miami News | Lifestyle Magazine | Politics News | Lifestyle Magazine Advertising Business Newspaper | Miami News | Lifestyle Magazine | Fashion Magazine | Digital Newspaper | Lifestyle Magazine | Woman Magazine | Lifestyle News | Politic News | Miami News | Lifestyle Magazine | Politics News | Lifestyle Magazine